Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Infectious Diseases: News, Opinions, Training ; 11(3):28-34, 2022.
Article in Russian | EMBASE | ID: covidwho-2325626

ABSTRACT

The COVID-19 pandemic continues to spread despite all the efforts of the medical community. The aim of the study - to identify the features of a new coronavirus infection (COVID-19) with lung tissue damage in men and women receiving inpatient treatment. Material and methods. The method of continuous sampling selected 225 patients admitted to inpatient treatment. The patients were divided in 2 groups: the 1st group - men (n=85), the 2nd group - women (n=140). Statistical processing was carried out using the IBM SPSS Statistics 22.0 program. Results. In a comprehensive study of the features of lung tissue damage by the new coronavirus infection SARS-CoV-2 in men and women was found that women received inpatient treatment more often, after ineffective outpatient treatment, the general serious condition at admission was more typical for women who had a positive result of a PCR-test for the detection of SARS-CoV-2 (p=0.038). In the presence of general clinical manifestations complaints of loss of sense of smell were more often presented by women (p=0.020). According to laboratory studies in the indicators of general clinical and biochemical blood tests, on average men often have higher levels of creatinine (p<0.001), women more often have elevated levels of ESR (p=0.003), erythrocytes (p<0.001), CRP (p=0.042) and decreased hemoglobin (p=0.029). Conclusion. In the first wave of the Wuhan pandemic of the SARS-CoV-2 virus strain women prevailed among patients admitted to inpatient treatment with lung tissue damage after ineffective outpatient treatment (p=0.038). There was a commonality in age and clinical manifestations, of the complaints in women, only loss of sense of smell was more common (p=0.020). The erythrocytosis detected in women, increased ESR and CRP, lower hemoglobin and creatinine levels are not specific for COVID-19. There were no statistically significant differences in the terms of hospitalization and the fatal outcome of the disease between men and women.Copyright © Eco-Vector, 2022.

2.
Yakut Medical Journal ; - (4):65-67, 2022.
Article in English | Web of Science | ID: covidwho-2236593

ABSTRACT

This article carried material about the results of the investigation of peripheral blood cellular immunity parameters in the COVID-19 patients with <= 30% lung damage hospitalizated in 2020 year. When infected with SARS-CoV-2 on the background of severe lymphopenia and neutrophilia were revealed the multidirectional changing in a cellular immunity parameters, the severity and dynamics of which can be determined by the initial type of immune system response.

3.
Infectious Diseases: News, Opinions, Training ; 11(3):28-34, 2022.
Article in Russian | Scopus | ID: covidwho-2206003

ABSTRACT

The COVID-19 pandemic continues to spread despite all the efforts of the medical community. The aim of the study – to identify the features of a new coronavirus infection (COVID-19) with lung tissue damage in men and women receiving inpatient treatment. Material and methods. The method of continuous sampling selected 225 patients admitted to inpatient treatment. The patients were divided in 2 groups: the 1st group – men (n=85), the 2nd group – women (n=140). Statistical processing was carried out using the IBM SPSS Statistics 22.0 program. Results. In a comprehensive study of the features of lung tissue damage by the new coronavirus infection SARS-CoV-2 in men and women was found that women received inpatient treatment more often, after ineffective outpatient treatment, the general serious condition at admission was more typical for women who had a positive result of a PCR-test for the detection of SARS-CoV-2 (p=0.038). In the presence of general clinical manifestations complaints of loss of sense of smell were more often presented by women (p=0.020). According to laboratory studies in the indicators of general clinical and biochemical blood tests, on average men often have higher levels of creatinine (p<0.001), women more often have elevated levels of ESR (p=0.003), erythrocytes (p<0.001), CRP (p=0.042) and decreased hemoglobin (p=0.029). Conclusion. In the first wave of the Wuhan pandemic of the SARS-CoV-2 virus strain women prevailed among patients admitted to inpatient treatment with lung tissue damage after ineffective outpatient treatment (p=0.038). There was a commonality in age and clinical manifestations, of the complaints in women, only loss of sense of smell was more common (p=0.020). The erythrocytosis detected in women, increased ESR and CRP, lower hemoglobin and creatinine levels are not specific for COVID-19. There were no statistically significant differences in the terms of hospitalization and the fatal outcome of the disease between men and women. © Eco-Vector, 2022.

4.
Klin Lab Diagn ; 66(11): 645-649, 2021 Nov 29.
Article in English | MEDLINE | ID: covidwho-1626762

ABSTRACT

In the context of a pandemic caused by the SARS-CoV-2 virus, for a patient with respiratory symptoms and bilateral lung damage, COVID-19 becomes the first disease in the differential diagnostic search. Pneumonia in COVID-19 shares many characteristics with Pneumocystis pneumonia. One of the possible markers of the severe course of COVID-19 is hepcidin, a peptide hormone that negatively regulates iron metabolism. There are no data on the value of hepcidin in Pneumocystis pneumonia in the published scientific literature. The purpose of this study is to conduct a comparative analysis of hepcidin in the blood serum of patients with pneumonia in COVID-19 and Pneumocystis pneumonia to clarify their pathogenetic features. A case-control observational study was conducted, including 68 patients with pneumonia in COVID-19 and 44 patients with HIV infection and Pneumocystis pneumonia (PCP/HIV). Determination of hepcidin was carried out by ELISA using the ELISA Kit for Hepcidin. Statistical data processing was carried out using the MedCalc 19.2.6 software. Results. Comparative analysis of serum hepcidin levels in the study groups showed that hepcidin is statistically significantly higher in PCP/HIV than in COVID-19 - the median value is 22 times higher (p <0.0001). When examining the ROC curve for hepcidin, it was found that this biomarker has a high diagnostic potential and indicates a higher probability of COVID-19 than PCP/HIV at values ≤768.044 pg / ml. In the context of the COVID-19 pandemic, it is necessary to remember about other diseases that manifest themselves with a similar clinical and radiological picture. COVID-19 and PCP/HIV share many similarities; the peptide hormone hepcidin has shown itself as a potential differential diagnostic marker between them, and therefore the need for further studies of hepcidin is justified, taking into account the severity of the course of COVID-19, the presence of comorbidities and in a comparative aspect with pathologies that «mimic¼ under COVID-19.


Subject(s)
COVID-19 , HIV Infections , Pneumonia, Pneumocystis , HIV Infections/complications , Hepcidins , Humans , Pandemics , Pneumonia, Pneumocystis/diagnosis , Pneumonia, Pneumocystis/epidemiology , SARS-CoV-2 , Serum
5.
Acta Biomedica Scientifica ; 6(4):74-86, 2021.
Article in Russian | Scopus | ID: covidwho-1518923

ABSTRACT

The new coronavirus infection (SARS-CoV-2), better known as COVID-19, quickly evolved into a worldwide pandemic with a significant public health burden. Currently, there are no approved drugs or preventive therapeutic strategies to combat infection. Decisions about prescribing many medications are made based on the results obtained in in vitro studies, or expert opinions. Most of the drugs currently used to treat COVID-19 are approved antivirals or antibodies against other diseases. However, there are hundreds of clinical studies underway around the world to discover effective treatments for COVID-19. This article summarizes the results of clinical studies of potential therapeutic drugs used as COVID-19 therapy. Based on this review, it can be concluded that there is still no high-quality evidence to support any of the drugs described below. Until the unambiguous results of randomized controlled trials are available, the use of any of the following drugs is not clinically proven as an effective treatment for COVID-19. © 2021 Scientific Centre for Family Health and Human Reproduction Problems. All Rights Reserved.

SELECTION OF CITATIONS
SEARCH DETAIL